European pharma ETF outperforms AstraZeneca by 10% within 9 months
Resolves: The iShares STOXX Europe 600 Health Care ETF (or equivalent) outperforms AstraZeneca's stock by at least 10 percentage points between 2026-07-12 and 2027-04-11, based on total return (price + dividends).
European pharma ETF outperforms AstraZeneca by 10% within 9 months
Market overview
AstraZeneca's pipeline premium is being questioned following a trial failure, while the broader European pharma sector may benefit from diversification. If the sector's ETF (e.g., iShares STOXX Europe 600 Health Care) gains traction, it could outperform AstraZeneca significantly as investors seek alternatives amid pipeline risk.
price prediction market
- Implied probability (Yes)
- 70%
- Closes
- 2027-04-11
About this prediction
Resolution criteria
The iShares STOXX Europe 600 Health Care ETF (or equivalent) outperforms AstraZeneca's stock by at least 10 percentage points between 2026-07-12 and 2027-04-11, based on total return (price + dividends).
Source: user-generated
More price markets
- Bitcoin price exceeds $150,000 by end of 2026 — 68% Yes
- Bitcoin price recovers to $50,000 by December 2026 — 62% Yes
- Bitcoin price exceeds $100,000 within 6 months of Clarity Act passage — 70% Yes
- Coinbase stock to rise 15% by June 2026 amid crypto regulation clarity — 72% Yes
- NY crypto tax revenue will exceed $200M in 2027 — 65% Yes
- Will stock drop >15% on next financing terms? — 45% Yes
- Will enGene raise additional equity financing before Q1 2027? — 80% Yes
- Trading volume on Kalshi’s crypto futures exceeds $500M in first month — 60% Yes